clinical trial · NCT07219953
A Study of Brenipatide in Participants With Alcohol Use Disorder
Eli Lilly and Company·phase3·recruiting·n = 1,100
Alcohol Use DisorderLY3537031Placebo
brief summary
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.
started
Oct 16, 2025
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Apr 17, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol